Hear from Gideon Lapidoth, CEO of Enzymit, Gita Reinitz, Principal at the newly formed NFX.bio, and Yizhen Dong, Partner at GFC's bio fund about the breakthroughs that have enabled us to read and write DNA like we've done with software and the changes that are coming.
